“It is a good transaction and a win-win deal from the outside for both. Sun will get access to Ranbaxy’s products and an entry into Japan (through Daiichi) which is a difficult market. Daiichi was not able to manage Ranbaxy’s regulatory problems. Sun would be able to manage this, as it has done in the past. The deal though may not trigger more local consolidations. We have done many in the past, and there has also been Torrent’s buy of Elder Pharma’s operations. There will continue to be individual transactions, but this will not be a trend”
Ajay Piramal
Chairman, Piramal Enterprises
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.